The initial therapy for advanced prostate cancer involves androgen ablation that leads to a reduction in TMPRSS2-ERG expression in tumors expressing this fusion protein; however, patients nearly invariably progress with development of mechanisms of androgen resistance and restore of TMPRSS2-ERG expression [121]. Here, TMPRSS2 is linked to Familial prostate cancer.